{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:16:56Z","timestamp":1790835416508,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T00:00:00Z","timestamp":1567814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Almirall Hermal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12883-019-1443-y","type":"journal-article","created":{"date-parts":[[2019,9,7]],"date-time":"2019-09-07T12:03:18Z","timestamp":1567857798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2736-7350","authenticated-orcid":false,"given":"Thomas","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Funke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"M\u00fcnch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"Kettemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Maier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertram","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annett","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Spittel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,7]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/S0140-6736(17)31287-4","volume":"390","author":"MA van Es","year":"2017","unstructured":"van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH. Amyotrophic lateral sclerosis. Lancet. 2017;390:2084\u201398.","journal-title":"Lancet"},{"key":"1443_CR2","doi-asserted-by":"publisher","first-page":"17071","DOI":"10.1038\/nrdp.2017.71","volume":"3","author":"O Hardiman","year":"2017","unstructured":"Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071. https:\/\/doi.org\/10.1038\/nrdp.2017.71 .","journal-title":"Nat Rev Dis Primers"},{"key":"1443_CR3","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1136\/jnnp.2010.235952","volume":"82","author":"A Chio","year":"2011","unstructured":"Chio A, Calvo A, Moglia C, Mazzini L, Mora G. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82:740\u20136.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1443_CR4","doi-asserted-by":"publisher","first-page":"e012054","DOI":"10.1136\/bmjopen-2016-012054","volume":"6","author":"P Talman","year":"2016","unstructured":"Talman P, Duong T, Vucic S, Mathers S, Venkatesh S, Henderson R, et al. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis\/motor neuron disease: Australian National Motor Neuron Disease observational cohort. BMJ Open. 2016;6:e012054. https:\/\/doi.org\/10.1136\/bmjopen-2016-012054 .","journal-title":"BMJ Open"},{"key":"1443_CR5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1615\/CritRevPhysRehabilMed.2013007945","volume":"25","author":"E Chang","year":"2013","unstructured":"Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T. A review of spasticity treatments: pharmacological and interventional approaches. Crit Rev Phys Rehabil Med. 2013;25:11\u201322.","journal-title":"Crit Rev Phys Rehabil Med"},{"key":"1443_CR6","doi-asserted-by":"publisher","unstructured":"Ashworth NL, Satkunam LE, Deforge D. Treatment for spasticity in amyotrophic lateral sclerosis\/motor neuron disease. Cochrane Database Syst Rev 2012;2:CD004156. https:\/\/doi.org\/10.1002\/14651858.CD004156 .","DOI":"10.1002\/14651858.CD004156"},{"key":"1443_CR7","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1097\/WCO.0000000000000135","volume":"27","author":"TM Jenkins","year":"2014","unstructured":"Jenkins TM, Hollinger H, McDermott CJ. The evidence for symptomatic treatments in amyotrophic lateral sclerosis. Curr Opin Neurol. 2014;27:524\u201331. https:\/\/doi.org\/10.1097\/WCO.0000000000000135 .","journal-title":"Curr Opin Neurol"},{"key":"1443_CR8","doi-asserted-by":"publisher","first-page":"CD011776","DOI":"10.1002\/14651858.CD011776.pub2","volume":"1","author":"L Ng","year":"2017","unstructured":"Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis\/motor neuron disease. Cochrane Database Syst Rev. 2017;1:CD011776. https:\/\/doi.org\/10.1002\/14651858.CD011776.pub2 .","journal-title":"Cochrane Database Syst Rev"},{"key":"1443_CR9","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1468-1331.2010.03328.x","volume":"18","author":"A Novotna","year":"2011","unstructured":"Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol. 2011;18:1122\u201331.","journal-title":"Eur J Neurol"},{"key":"1443_CR10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/1352458511419700","volume":"18","author":"W Notcutt","year":"2011","unstructured":"Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols). Mult Scler J. 2011;18:219\u201328.","journal-title":"Mult Scler J"},{"key":"1443_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40265-017-0720-6","volume":"77","author":"GM Keating","year":"2017","unstructured":"Keating GM. Delta-9-tetrahydrocannabinol\/Cannabidiol Oromucosal spray (Sativex\u00ae): a review in multiple sclerosis-related spasticity. Drugs. 2017;77:563\u201374. https:\/\/doi.org\/10.1007\/s40265-017-0720-6 .","journal-title":"Drugs"},{"key":"1443_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1474-4422(18)30406-X","volume":"18","author":"N Riva","year":"2019","unstructured":"Riva N, Mora G, Sorar\u00f9 G, Lunetta C, Ferraro OE, Falzone Y, et al. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019;18:155\u201364.","journal-title":"Lancet Neurol"},{"key":"1443_CR13","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297.","journal-title":"PLoS Med"},{"key":"1443_CR14","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1080\/146608200300079536","volume":"1","author":"BR Brooks","year":"2000","unstructured":"Brooks BR, Miller RG, Swash M, Munsat TL. World Federation of Neurology Research Group on Motor Neuron Diseases. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293\u20139.","journal-title":"Amyotroph Lateral Scler Other Motor Neuron Disord"},{"key":"1443_CR15","unstructured":"https:\/\/www.ambulanzpartner.de\/ . Accessed 5 Apr 2019."},{"key":"1443_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0304-3959(93)90148-I","volume":"55","author":"MP Jensen","year":"1993","unstructured":"Jensen MP, McFarland CA. Increasing the reliability and validity of pain intensity measurement in chronic pain patients. Pain. 1993;55:195\u2013203.","journal-title":"Pain"},{"key":"1443_CR17","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1053\/jpmn.2001.23746","volume":"2","author":"CS Rodriguez","year":"2001","unstructured":"Rodriguez CS. Pain measurement in the elderly: a review. Pain Manag Nurs. 2001;2:38\u201346.","journal-title":"Pain Manag Nurs"},{"key":"1443_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.jpain.2016.11.008","volume":"18","author":"JL Goulet","year":"2017","unstructured":"Goulet JL, Buta E, Carroll C, Brandt CA. Statistical models for the analysis of zero-inflated pain intensity numeric rating scale data. J Pain. 2017;18:340\u20138.","journal-title":"J Pain"},{"key":"1443_CR19","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1097\/j.pain.0000000000000567","volume":"157","author":"JL Goulet","year":"2016","unstructured":"Goulet JL, Kerns RD, Bair M, Becker W, Brennan P, Burgess DJ, al e. The musculoskeletal diagnosis cohort: Examining pain and pain care among veterans. Pain. 2016;157:1696\u2013703.","journal-title":"Pain"},{"key":"1443_CR20","first-page":"45","volume-title":"Reichheld F, Markey R. the ultimate question 2.0: how net promoter companies thrive in a customer-driven world","author":"M Reichheld","year":"2011","unstructured":"Reichheld M. The measure of success. In: Reichheld F, Markey R. the ultimate question 2.0: how net promoter companies thrive in a customer-driven world. Boston: Harvard Business Review Press; 2011. p. 45\u201360."},{"key":"1443_CR21","unstructured":"http:\/\/www.netpromotersystem.com\/ . Accessed 5 Apr 2019."},{"key":"1443_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1477-7525-2-12","volume":"2","author":"MJ Atkinson","year":"2004","unstructured":"Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl 1","key":"1443_CR23","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1111\/j.1524-4733.2005.00066.x","volume":"8","author":"M Atkinson","year":"2005","unstructured":"Atkinson M, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers. Value Health. 2005;8(Suppl 1):S9\u2013S24.","journal-title":"Value Health"},{"key":"1443_CR24","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1477-7525-7-36","volume":"7","author":"M Bharmal","year":"2009","unstructured":"Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated treatment satisfaction questionnaire for medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7:36.","journal-title":"Health Qual Life Outcomes"},{"key":"1443_CR25","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1080\/21678421.2018.1431786","volume":"19","author":"A Funke","year":"2018","unstructured":"Funke A, Spittel S, Grehl T, Grosskreutz J, Kettemann D, Petri S, et al. Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:342\u201350.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1443_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/ane.12910","volume":"138","author":"K Milinis","year":"2018","unstructured":"Milinis K, Tennant A, Mills RJ, Al-Chalabi A, Burke G, Dick DJ, et al. Development and validation of spasticity index-amyotrophic lateral sclerosis. Acta Neurol Scand. 2018;138:47\u201354.","journal-title":"Acta Neurol Scand"},{"key":"1443_CR27","doi-asserted-by":"publisher","first-page":"CD004157","DOI":"10.1002\/14651858.CD004157.pub2","volume-title":"Treatment for cramps in amyotrophic lateral sclerosis\/motor neuron disease. Cochrane database Syst rev","author":"R Baldinger","year":"2012","unstructured":"Baldinger R, Katzberg HD, Weber M. Treatment for cramps in amyotrophic lateral sclerosis\/motor neuron disease. Cochrane database Syst rev; 2012. p. CD004157. https:\/\/doi.org\/10.1002\/14651858.CD004157.pub2 ."},{"key":"1443_CR28","first-page":"CD005226","volume":"6","author":"J Brettschneider","year":"2013","unstructured":"Brettschneider J, Kurent J, Ludolph A. Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;6:CD005226.","journal-title":"Cochrane Database Syst Rev"},{"key":"1443_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.pnpbp.2015.07.001","volume":"64","author":"SP Alexander","year":"2016","unstructured":"Alexander SP. Therapeutic potential of cannabis-related drugs. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:57\u201366.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"1443_CR30","doi-asserted-by":"crossref","first-page":"E755","DOI":"10.36076\/ppj.20.5.E755","volume":"20","author":"J Aviram","year":"2017","unstructured":"Aviram J, Samuelly-Leichtag G. Efficacy of cannabis-based medicines for pain management: a systematic review and meta-analysis of randomized controlled trials. Pain Physician. 2017;20:E755\u201396.","journal-title":"Pain Physician"},{"key":"1443_CR31","doi-asserted-by":"publisher","unstructured":"DasMahapatra P, Raja P, Gilbert J, Wicks P. Clinical trials from the patient perspective: survey in an online patient community. BMC Health Serv Res. 2017. https:\/\/doi.org\/10.1186\/s12913-017-2090-x .","DOI":"10.1186\/s12913-017-2090-x"},{"key":"1443_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1080\/0284186X.2018.1438654","volume":"57","author":"H Melissant","year":"2018","unstructured":"Melissant H, Verdonck-de Leeuw I, Lissenberg-Witte B, Konings IR, Cuijpers P, Van Uden-Kraan CF. \u2018Oncokompas\u2019, a web-based self-management application to support patient activation and optimal supportive care: a feasibility study among breast cancer survivors. Acta Oncol. 2018;57:924\u201334.","journal-title":"Acta Oncol"},{"key":"1443_CR33","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/jnnp.2009.200642","volume":"81","author":"M Weber","year":"2010","unstructured":"Weber M, Goldman B, Truniger S. Tetrahydrocannabinol (THC) for cramps in amyotrophic lateral sclerosis: a randomised, double-blind crossover trial. J Neurol Neurosurg Psychiatry. 2010;81:1135\u201340.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1443_CR34","doi-asserted-by":"publisher","first-page":"e10099","DOI":"10.2196\/10099","volume":"5","author":"R Meyer","year":"2018","unstructured":"Meyer R, Spittel S, Steinfurth L, Funke A, Kettemann D, M\u00fcnch C, et al. Patient-reported outcome of physical therapy in amyotrophic lateral sclerosis: observational online study. JMIR Rehabil Assist Technol. 2018;5:e10099. https:\/\/doi.org\/10.2196\/10099 .","journal-title":"JMIR Rehabil Assist Technol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1443-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-019-1443-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-019-1443-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T20:55:12Z","timestamp":1664312112000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-019-1443-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1186\/s12883-019-1443-y","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,7]]},"assertion":[{"value":"30 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Medical Ethics Committee of the Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Germany under the number EA1\/219\/15. A signed patient information and informed consent form was obtained from all participating patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This work was supported Almirall Hermal GmbH, the manufacturer of Tetrahydrocannabinol\/Cannabidiol (THC:CBD). TM and CM are founders of the internet platform Ambulanzpartner and hold shares of Ambulanzpartner Soziotechnologie APST GmbH. TM received consultancy fees from Cytokinetics, Biogen, Mitsubishi Tanabe, TEVA and Desitin Arzneimittel GmbH.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}